Clinical Trials Logo

Iris Melanoma clinical trials

View clinical trials related to Iris Melanoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02336763 Terminated - Iris Melanoma Clinical Trials

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Start date: October 2014
Phase: N/A
Study type: Interventional

This clinical trial studies giving radiation therapy to the liver in patients with uveal (eye) melanoma who have a specific chromosome loss (monosomy 3) or are DecisionDx Class 2 and therefore more likely to have their disease spread from the eye to the liver. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Early radiation to the liver may reduce the development of tumors in the liver and the overall risk of disease recurrence.

NCT ID: NCT01730157 Terminated - Liver Metastases Clinical Trials

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Start date: December 2012
Phase: Phase 0
Study type: Interventional

This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radioembolization together with ipilimumab may kill more tumor cells in patients with uveal melanoma